PMID- 34243680
OWN - NLM
STAT- MEDLINE
DCOM- 20220211
LR  - 20220211
IS  - 1521-0669 (Electronic)
IS  - 0888-0018 (Linking)
VI  - 39
IP  - 1
DP  - 2022 Feb
TI  - Clinical characteristics and successful treatment outcomes of children and 
      adolescents with Kaposi sarcoma in Southwestern Tanzania.
PG  - 28-47
LID - 10.1080/08880018.2021.1936315 [doi]
AB  - The HIV/AIDS epidemic has driven the rise in cases of Kaposi sarcoma (KS) among 
      children and adolescents living with HIV in countries with high Human 
      gammaherpesvirus 8 (HHV-8) seroprevalence, such as Tanzania, where specialized 
      oncology programs are sparse. Consequently, descriptions of successful treatment 
      of KS in children and adolescents by general pediatricians are important. A 
      retrospective analysis was performed of children and adolescents diagnosed with 
      KS and treated with chemotherapy and combination antiretroviral therapy (cART) at 
      the Baylor College of Medicine Children's Foundation Tanzania Center of 
      Excellence - Mbeya between 2011 and 2017. Sixty-one patients were diagnosed with 
      KS with a median age of 12.6 years (interquartile range (IQR) 9.4 - 15.5). 
      Diagnosis was confirmed by histopathology in 36% (22/61). Among HIV positive 
      patients (59/61), 78% (46/59) were on cART at KS diagnosis. Severe 
      immunosuppression was present in 63% (35/56) of those with CD4 data and 44% 
      (27/61) had SAM. Advanced-stage T1 disease was present in 64% (39/61), including 
      28% (17/61) with visceral/disseminated KS. Two-year estimated overall survival 
      (OS) was 72% (95% Confidence Interval (CI): 58%-82%) and median follow up for 
      survivors was 25.7 months (IQR 14.2-53.8). No patients were lost to follow up. 
      Two-year OS was 63% (95% CI: 44%-77%) in patients with severe immune suppression 
      and 60% (95% CI: 37%-76%) in patients with SAM. Among patients with 
      visceral/disseminated KS, 53% (9/17) survived. This retrospective analysis 
      demonstrated favorable outcomes in a complex cohort of children and adolescents 
      with KS treated with chemotherapy by general pediatricians in Tanzania.
FAU - Campbell, L R
AU  - Campbell LR
AUID- ORCID: 0000-0002-3868-9312
AD  - Baylor College of Medicine International Pediatric AIDS Initiative at, Texas 
      Children's Hospital, Houston, Texas, USA.
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
FAU - El-Mallawany, N K
AU  - El-Mallawany NK
AUID- ORCID: 0000-0001-6115-1046
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
FAU - Slone, J S
AU  - Slone JS
AUID- ORCID: 0000-0002-0700-7104
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
FAU - Malingoti, B M
AU  - Malingoti BM
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
FAU - Mehta, P S
AU  - Mehta PS
AUID- ORCID: 0000-0001-5695-6907
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
FAU - Scheurer, M E
AU  - Scheurer ME
AUID- ORCID: 0000-0002-8379-6088
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
AD  - Center for Epidemiology and Population Health, Department of Pediatrics, Baylor 
      College of Medicine, Houston, Texas, USA.
FAU - Bacha, J M
AU  - Bacha JM
AUID- ORCID: 0000-0002-1093-5227
AD  - Baylor College of Medicine International Pediatric AIDS Initiative at, Texas 
      Children's Hospital, Houston, Texas, USA.
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
FAU - Peckham-Gregory, E C
AU  - Peckham-Gregory EC
AUID- ORCID: 0000-0002-7593-8381
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's 
      Hospital, Houston, Texas, USA.
AD  - Center for Epidemiology and Population Health, Department of Pediatrics, Baylor 
      College of Medicine, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20210709
PL  - England
TA  - Pediatr Hematol Oncol
JT  - Pediatric hematology and oncology
JID - 8700164
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - Retrospective Studies
MH  - *Sarcoma, Kaposi/drug therapy/epidemiology
MH  - Seroepidemiologic Studies
MH  - Tanzania/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chemotherapy
OT  - HIV
OT  - Kaposi sarcoma
OT  - Sub-Saharan Africa
OT  - children
EDAT- 2021/07/11 06:00
MHDA- 2022/02/12 06:00
CRDT- 2021/07/10 05:23
PHST- 2021/07/11 06:00 [pubmed]
PHST- 2022/02/12 06:00 [medline]
PHST- 2021/07/10 05:23 [entrez]
AID - 10.1080/08880018.2021.1936315 [doi]
PST - ppublish
SO  - Pediatr Hematol Oncol. 2022 Feb;39(1):28-47. doi: 10.1080/08880018.2021.1936315. 
      Epub 2021 Jul 9.